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Suppressor of cytokine signaling 1 (SOCS1) is a negative feedback inhibitor of 
cytoplasmic Janus kinase and signal transducer and activator of transcription (STAT) 
signaling. SOCS1 also contains a nuclear localization sequence (NLS), yet, the in vivo 
importance of nuclear translocation is unknown. We generated transgenic mice 
containing mutated Socs1ΔNLS that fails to translocate in the cell nucleus (MGLtg mice). 
Whereas mice fully deficient for SOCS1 die within the first 3 weeks due to excessive 
interferon signaling and multiorgan inflammation, mice expressing only non-nuclear 
Socs1ΔNLS (Socs1−/−MGLtg mice) were rescued from early lethality. Canonical interferon 
gamma signaling was still functional in Socs1−/−MGLtg mice as shown by unaltered 
tyrosine phosphorylation of STAT1 and whole genome expression analysis. However, a 
subset of NFκB inducible genes was dysregulated. Socs1−/−MGLtg mice spontaneously 
developed low-grade inflammation in the lung and had elevated Th2-type cytokines. 
Upon ovalbumin sensitization and challenge, airway eosinophilia was increased in 
Socs1−/−MGLtg mice. Decreased transepithelial electrical resistance in trachea epithelial 
cells from Socs1−/−MGLtg mice suggests disrupted epithelial cell barrier. The results 
indicate that nuclear SOCS1 is a regulator of local immunity in the lung and unravel a so 
far unrecognized function for SOCS1 in the cell nucleus.
Keywords: rodent, inflammation, signal transduction, transgenic mice, lung, sOcs1
inTrODUcTiOn
The suppressor of cytokine signaling (SOCS) family is important for negative feedback inhi-
bition of Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) 
signaling. All eight members, namely SOCS1–7 and CIS, share key structural elements such 
as the central cytokine-inducible Src-homology 2 (SH2) domain and the shared C-terminal 
SOCS-box (1,  2). Both SOCS1 and SOCS3 additionally contain a kinase inhibitory region 
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(KIR) by which they can act as a pseudosubstrate for JAKs 
(3). SOCS1 was first described in 1997 as a negative feedback 
inhibitor of cytoplasmic JAK/STAT signaling (4–6). By the 
means of the extended SH2 subdomain (eSS) and the KIR, 
SOCS1 directly binds to JAK2, thereby inhibiting its catalytic 
activity (3). SOCS1 has further been shown to occupy binding 
sites for STATs by interacting with interferon receptor domains 
(7, 8). Finally, the SOCS box in SOCS1 mediates interactions 
with elongins B and C and acts as an E3 ubiquitin ligase that 
targets JAKs or cytokine receptor complexes for proteasomal 
degradation (9, 10). In addition to JAK/STAT signaling, SOCS1 
has been shown to act as a cross talk inhibitor for TLR signaling 
pathways (11, 12). Besides indirect paracrine inhibition of 
TLR signaling by IFNβ (13), SOCS1 additionally contributes 
to direct negative regulation by interacting with components 
of the TLR signaling pathway (12, 14).
Canonical IFNγ signaling functions by binding to the IFNγ 
receptor complex, activating Janus kinases (JAK1/2), and subse-
quent phosphorylation of STAT1 that dimerizes and translocates 
into the nucleus. Once in the nucleus, activated pY-STAT1 
binds to gamma-activated sequence (GAS) elements within the 
promoters of IFNγ-responsive genes (ISGs) – mostly, “canoni-
cal” antiviral genes (15, 16). While pY-STAT1 is thought to be 
pivotal for the IFNγ response, a number of studies have shown 
that pY-STAT1-independent pathways also exist (17–19). There 
is emerging evidence that STAT-independent pathways play 
important roles in mediating signals for the generation of IFNγ-
responses such as the mitogen-activated protein kinase (MAPK) 
or PI3K/AKT pathway (20). It has been previously shown that 
IFNAR1, TYK2, and STAT1 may translocate into the nucleus 
(21, 22). The presence of unphosphorylated STAT1 in the cell 
nucleus has been shown to increase expression of only a subset 
of “non-canonical” IFNγ-induced genes that are pY-STAT1-
independent (23).
Socs1−/− mice die within 2–3  weeks due to unlimited IFNγ 
signaling leading to multiorgan inflammation (24–26). Deletion 
of the SOCS box of SOCS1 delays the onset of the disease (27). 
Alleviation from the lethal phenotype of Socs1−/− mice can be 
achieved by backcrossing to IFNγ−/−mice; however, these mice 
develop polycystic kidneys as well as chronic inflammation (28). 
Moreover, Socs1−/− mice can be rescued by backcrossing to either 
STAT4−/−, or STAT6−/− mice (25, 29), or Rag−/− mice (30), reveal-
ing an important role of SOCS1 in T cells. Since Socs1−/− mice 
have defective thymocyte development, and overexpression of 
Socs1 impairs pre-TCR-induced thymocyte proliferation, inhi-
bition of cytokine signaling has important influence on T cell 
differentiation (31, 32).
In 2008, a nuclear localization sequence (NLS) has been 
identified in SOCS1 located between the central SH2 domain 
and the SOCS box (amino acids 159–173). The NLS resulted 
in translocation of the protein into the cell nucleus (33, 34). 
Substitution of this sequence with the respective region of 
SOCS3 showed loss of nuclear localization, whereas fusion 
of the SOCS1–NLS to the cytoplasmic SOCS family member 
CIS induced nuclear localization (33). It has been shown that 
SOCS1 directly interacts with the tumor suppressor p53 lead-
ing to activation of p53 via phosphorylation (35). Moreover, 
SOCS1 induces proteasomal degradation of NFκB (36, 37) 
and, in particular, it interacts with the NFκB subunit p65 in 
the cell nucleus, thereby limiting induction of a subset of NFκB 
dependent genes (38).
However, the function of SOCS1 in the cell nucleus in  vivo 
remains elusive. Therefore, we generated a transgenic mouse 
that only expresses a non-nuclear mutant SOCS1. Mice with 
transgenic expression of a bacterial artificial chromosome (BAC) 
containing a mutated Socs1 locus with non-nuclear Socs1ΔNLS, 
eGFP, and LuciferaseCBG99 (MGL) were generated and back-
crossed to Socs1−/− mice. Socs1−/−MGLtg mice survived the early 
lethal phenotype of Socs1−/− mice, showed unaltered canonical 
IFNγ-signaling, yet, displayed signs of low-grade airway inflam-
mation and Th2 deviation. Decreased transepithelial electrical 
resistance (TER) in trachea epithelial cells from Socs1−/−MGLtg 
mice suggests disrupted epithelial integrity. Socs1−/−MGLtg mice 
present a valuable tool to study the nuclear function of SOCS1 
in  vivo and allow investigating local immune regulation in the 
lung by nuclear SOCS1.
MaTerials anD MeThODs
Mice
C57BL/6 mice were purchased from Charles River Laboratories. 
Breeding occurred under specific pathogen-free conditions in 
the animal facility (IBF, Heidelberg, Germany). Socs1+/− mice 
(C57/Bl6.129Sv-Socs1tmWsa/Uhg) were first described by 
Starr et  al. (26). MGL-transgenic mice were generated by 
pronucleus injection using a BAC containing a part of chromo-
some #16 (10.78–10.80  Mb) including a mutated Socs1 locus 
with non-nuclear Socs1ΔNLS, eGFP (codon optimized for 
mouse and human), and LuciferaseCBG99 (Click Beetle Green 
from Pyrophorus plagiophalam), termed MGL (RP23-360O7). 
Pronucleus injection resulted in 12 transgenic founder mice, 
C57Bl6-tg(Socs1-MGL)Uhg. This work was done by Prof. 
Dr. Bernd Arnold and Günter Küblbeck (DKFZ, Heidelberg, 
Germany) in cooperation with Frank Zimmermann (IBF) and 
Patrick Walker. Mice are genotyped at an age of 2 weeks using 
PCR detecting Socs1 wild-type (wt), Socs1 knockout, Socs1 MGL, 
and β2microglobulin (β2M) (primer sequences, see Table S1 in 
Supplementary Material). Breeding, sacrificing, and dissection 
were approved and experiments properly recorded and reported 
to the regional commission in Karlsruhe (permit number 
35-9185.81/G-54/14).
reagents
RPMI 1640 was purchased from Biochrom (Berlin, Germany). 
FCS was from Life Technologies (Carlsbad, CA, USA) and 
Penicillin and streptomycin were from PAA Laboratories 
(Pasching, Austria). PBS was obtained from PAN-Biotech 
(Aidenbach, Germany). IFNγ was purchased from Peprotech 
(#315-05, Hamburg, Germany), polyinosinic–polycytidylic acid 
(pI:C) from InvivoGen (Toulouse, France) and phosphorothioate-
modified CpG-oligonucleotide 1668 from TIB Molbiol (Berlin, 
Germany). LPS from Salmonella minnesota was kindly provided 
by U. Seydel (Division of Biophysics, Research Center Borstel, 
Borstel, Germany).
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cell culture, Transfection, and stimulation
RAW264.7 or NIH cells were cultured at 37°C and 5% CO2 in 
RPMI or DMEM, respectively. Cell culture medium was further 
supplemented with 10% (v/v) heat-inactivated fetal calf serum 
(FCS), penicillin (50  units/ml), and streptomycin (50  μg/ml) 
(P/S). For transfection of RAW264.7 or NIH cells, the transfection 
reagents JetPRIME (Polyplus, Illkirch, France) or PeqFect (peqlab 
Biotechnology, Erlangen, Germany) were used and transfection 
was performed according to the manufacturer’s protocol. Bone 
marrow-derived macrophages (BMM) were isolated from mice as 
described previously (39). Briefly, bone marrow cells were seeded 
into a 14.5 cm dish in DMEM plus FCS and P/S and differentiated 
using 30% (v/v) L929 supernatant (containing M-CSF) for 7 days. 
For cycloheximide (CHX) chase, 1 × 106 BMMs were stimulated 
with IFNγ for 6  h and chased with 100  μg/ml CHX (Merck 
Millipore, MA, USA).
immunofluorescence Microscopy
NIH cells were grown on μ-slides (8-well, ibidi, Martinsried, 
Germany) and transfected with 0.5  μg GFP-Socs1 or GFP-
Socs1ΔNLS using PeqFect (peqlab Biotechnology, Erlangen, 
Germany). Where indicated, cells were stained with Hoechst 
(1 μg/ml) for 2 min or with CellMask™ Plasma Membrane Stain 
(ThermoFisher Scientific, Waltham, MA, USA, 1:1000) for 10 min 
at room temperature. Coverslips were mounted and analyzed by 
microscopy using a Leica TCS SP5 confocal microscope (Leica 
Microsystems, Wetzlar, Germany) equipped with a 488- and 
561-nm laser, spectrophotometer prism, tunable detectors, and a 
HCX PL APO 63×/1.4 oil objective. All channels were recorded 
in a sequential order to avoid emission cross talk. A z-stack was 
recorded and presented as an overlay using ImageJ (National 
Institutes of Health). For quantification of the fluorescence, a 
region of interest (ROI) was set around the nucleus or the cyto-
plasm of a cell and intensity of the fluorescence was examined in 
a z-stack using ImageJ.
Quantitative rT-Pcr
Total RNA from 2.5 × 105 cells was isolated using the peqGOLD 
RNA Kit (peqlab Biotechnology, Erlangen, Germany) according 
to the manufacturer’s protocol. After reverse transcription into 
cDNA using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA), 5 μl cDNA (diluted 
1:10) was used as template in a quantitative real-time PCR using 
SYBR Green FAST Mix (Applied Biosystems). Amplification 
and measurement was done in a StepOne Plus RT-PCR cycler 
(Applied Biosystems) in a 96-well format. Specificity of qPCR 
was controlled by non-template as well as no-RT samples and 
analysis of melting curves. Results are shown relative to the 
housekeeping gene β-Actin (ActB). Primer sequences are given 
in Table S1 in Supplementary Material. qPCR for Socs1 wt 
was performed with TaqMan Fast Universal PCR Master Mix 
(Applied Biosystems) in combination with a forward primer 
(P1) binding in the SH2 domain and a reverse primer (P2) 
binding in the SOCS box and a FAM-labeled probe binding in 
the NLS of Socs1. SYBR green dye in combination with P1 and a 
reverse primer (P3) within the modified NLS region were used 
for the detection of Socs1ΔNLS. For detection of total Socs1 (both 
Socs1 and Socs1ΔNLS), the primers P1 and P2 were used. This 
qPCR strategy allows for specific detection of Socs1, Socs1ΔNLS, 
or total Socs1. The amplification efficiencies for both Socs1 wt 
(1.68) and Socs1ΔNLS (1.88) were adjusted for differences.
Western Blotting
Also, 1  ×  106 BMMs or RAW264.7 cells were stimulated as 
indicated, subsequently washed with PBS, and lysed in Laemmli 
buffer [400 mM Tris–HCl, pH 6.8, 20% (v/v) β-mercaptoethanol, 
40% (v/v) glycerol, 8% (w/v) SDS, and 0.4% (v/v) bromophenol 
blue]. After incubation for 10  min at 98°C, equal amounts of 
lysates were fractionated by 10% polyacrylamide gel (SDS-
PAGE) and electrotransferred to Nitrocellulose membranes 
by a semidry blotting procedure [buffer: 25 mM Tris, 192 mM 
Glycin, 10% (v/v) methanol; 2.5  mA/cm2 for 1  h 15  min]. 
Blocking of unspecific binding was performed using 5% BSA 
solution in 1× TBST [1× TBS, 0.05% (v/v) Tween-20] for at least 
1 h. Membranes were stained with antibodies against pY-STAT1 
(Tyr701, #9167), STAT1 (#9172), IκBα (#9242), β-Actin (#4970) 
(Cell Signaling, Leiden, Netherlands; 1:1000), or hybridoma cell 
supernatant for SOCS1 detection (hybridoma cells newly gener-
ated by immunizing mice against the peptide RRITRASALLDA, 
Abmart, Shanghai, 1:20 dilution) overnight at 4°C. After 
three 10 min washing steps in 1× TBST at room temperature, 
blots were incubated with secondary antibodies for 1  h at RT 
[HRP-linked anti-mouse or anti-rabbit (Cell Signaling, Leiden, 
Netherlands)], followed by additional three 10  min washing 
steps in 1× TBST at room temperature. Proteins were detected 
using an enhanced chemiluminescence system (Western light-
ning™ plus ECL, Perkin-Elmer, Rodgau, Germany). Gels were 
imaged digitally, and contrast adjustments were applied to all 
parts of a figure. The prestained molecular weight marker was 
imaged separately (using transmitted light) and aligned to the 
digital images of the blots. The ladder is represented on the blots 
as black bars. Where indicated, membranes were stripped and 
reprobed. Densitometry was performed using ImageJ software 
(National Institutes of Health).
immunohistochemistry
For immunohistochemistry, lungs were fixed overnight in 4% 
(v/v) formalin and embedded in paraffin. Two micrometers lung 
sections were cut and stained for SOCS1 using the DAB staining 
method (Abcam, Cambridge, UK or Dako, Glostrup, Denmark). 
After deparaffination, demasking of the antibody followed 
using either citrate buffer [10 mM sodium citrate, 0.05% (v/v) 
Tween 20, pH 6.0] or EDTA buffer [1 mM EDTA, pH 8.0] for 
15–45 min in a steamer. Incubation with peroxidase-blocking 
solution and protein blocking solution was followed by incuba-
tion with the anti-SOCS1 antibody at varying concentrations 
(1:50–1:2000) at 4°C overnight. The commercially available 
antibodies from cell signaling (#3950, Leiden, Netherlands), 
Abcam (#ab-9870, Cambridge, UK), and Santa Cruz (#sc-9021, 
Santa Cruz Biotechnology, Heidelberg, Germany) were tested 
as well as hybridoma cell supernatant (newly generated by 
immunizing mice against the peptide RRITRASALLDA, Abmart, 
Shanghai) and a newly generated antibody against recombinant 
SOCS1 (generated against recombinant SOCS1 by immunizing 
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mice at Charles River, Chatillon-sur-Chalaronne, Ecully, France). 
On the next day, incubation with serum corresponding to the 
species of the secondary antibody followed. Incubation with the 
secondary antibody (goat anti-rabbit antibody or goat anti-mouse 
antibody) was performed for 30 min. After washing, sections were 
incubated with the chromogen (liquid diaminobenzidine and 
peroxide buffer) until a reaction was visible. Slides were coun-
terstained with hematoxylin to provide nuclear and morphologic 
detail and mounted. Lung sections of Socs1−/− mice were used as 
a negative control.
Flow cytometry
The 2.5 × 105 BMMs were harvested in PBS plus 2% (v/v) FCS and 
analyzed by FACSCanto flowcytometer gating on GFP positive 
cells (BD Bioscience, Heidelberg. Germany).
luciferase activity assay
The 2.5 × 105 BMMs were lysed in Luciferase lysis buffer [1% (v/v) 
Triton X-100, 25 mM Glycyl-Glycine (pH 7.8), 15 mM MgSO4, 
4 mM EGTA, and 1 mM DTT]. After injection of Luciferase assay 
buffer [25  mM K3PO4 (pH 7.8), 0.225  mM MgSO4, 0.08  mM 
EGTA, 2  mM ATP, 1  mM DTT, and 0.125  mM glycylglycine] 
to each well, activities in the lysates were measured using a 
luminometer (LUMIstar OPTIMA system, BMG LABTECH). 
Luminescent units are presented per microgram as determined 
by calorimetric Bradford assay using the Rotiquant reagent (Roth 
GmbH, Karlsruhe, Germany).
Whole-genome expression analysis
Total RNA from 2.5 ×  105 BMMs was isolated as described 
above. The quality of total RNA was checked by gel analysis 
using the total RNA Nano chip assay on an Agilent 2100 
Bioanalyzer (Agilent Technologies GmbH, Berlin, Germany). 
Only samples with RNA index values greater than 8.5 were 
selected for expression profiling. RNA concentrations were 
determined using the NanoDrop spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA). The laboratory work 
was done in the Genomics and Proteomics Core Facility at 
the German Cancer Research Center, Heidelberg, Germany 
(DKFZ). Biotin-labeled cRNA samples for hybridization on 
Illumina Mouse Sentrix-8 BeadChip arrays (Illumina, Inc.) 
were prepared according to Illumina’s recommended sample 
labeling procedure based on the modified Eberwine protocol 
(40). In brief, 300 ng total RNA was used for complementary 
DNA (cDNA) synthesis, followed by an amplification/labeling 
step (in vitro transcription) to synthesize biotin-labeled cRNA 
according to the Illumina® Total Prep™ RNA Amplification Kit 
(Life Technologies). Biotin-16-UTP was purchased from Roche 
Applied Science, Penzberg, Germany. The cRNA was column 
purified according to TotalPrep RNA Amplification Kit, and 
eluted in 60 μl of water. Quality of cRNA was controlled using 
the RNA Nano Chip Assay on an Agilent 2100 Bioanalyzer and 
spectrophotometrically quantified (NanoDrop). Hybridization 
was performed at 58°C, in GEX-HCB buffer (Illumina, Inc.) at a 
concentration of 100 ng cRNA/μl, unsealed in a wet chamber for 
20 h. Spike-in controls for low, medium, and highly abundant 
RNAs were added, as well as mismatch control and biotinylation 
control oligonucleotides. Microarrays were washed once in high 
temp wash buffer (Illumina, Inc.) at 55°C and then twice in 
E1BC buffer (Illumina, Inc.) at room temperature for 5 min (in 
between washed with ethanol at room temperature). After block-
ing for 5 min in 4 ml of 1% (wt/vol) Blocker Casein in phosphate 
buffered saline Hammarsten grade (Pierce Biotechnology, Inc., 
Rockford, IL, USA), array signals were developed by a 10 min 
incubation in 2  ml of 1  μg/ml Cy3-streptavidin (Amersham 
Biosciences, Buckinghamshire, UK) solution and 1% blocking 
solution. After a final wash in E1BC, the arrays were dried and 
scanned. Microarray scanning was done using an iScan array 
scanner. Data extraction was done for all beads individually, and 
outliers were removed when >2.5 median absolute deviation 
(MAD). All remaining data points were used for the calculation 
of the mean average signal for a given probe, and SD for each 
probe was calculated (ArrayExpress accession E-MTAB-4938). 
Data was processed using R, including log2 transformation of 
the data, significance (p ≤  0.05), and fold change (log2 ≤ −1 
or ≥1) filtered. Data were normalized to remove systematic 
variation and background subtraction. Pathway annotation was 
performed using the Protein Analysis through Evolutionary 
Relationships (PANTHER) classification system and transcrip-
tion factor binding sites (TFBS) among the differentially regu-
lated genes were analyzed using the overrepresentation analysis 
tool oPOSSUM.
enzyme-linked immunosorbent assay
The 2.5 × 105 CD11c+ cells were stimulated as indicated in 96-well 
plates in 200 μl RPMI supplemented with 10% (v/v) FCS and 
P/S. Supernatants were harvested and analyzed for cytokines by 
commercially available enzyme-linked immunosorbent assay 
(ELISA) kits for TNFα and IL-12p40 (BD Biosciences, Heidelberg, 
Germany). Cytokines were detected by measuring the absorb-
ance at 490 nm with a 650 nm reference in a photometer (Sunrise 
reader, Tecan, Salzburg, Austria). Cytokine concentrations were 
calculated according to a standard dilution of the respective 
recombinant cytokines using Magellan V 5.0 software (Tecan, 
Salzburg, Austria).
OVa sensitization and challenge
Mice were sensitized to ovalbumin (OVA) by three i.p. injections 
of 10  μg OVA (OVA grade VI; Sigma-Aldrich, Deisenhofen, 
Germany) adsorbed to 150 μg aluminum hydroxide (Imject Alum; 
Thermo, Rockford, IL, USA) on days 1, 14, and 21. Mice were 
exposed three times to an OVA (OVA grade V; Sigma-Aldrich) 
aerosol [1% (w/v) in PBS] on days 26, 27, and 28 to induce acute 
allergic airway inflammation (41). Sham sensitization and chal-
lenges were carried out using sterile PBS. Mice were sacrificed 
on day 29 by cervical dislocation under deep anesthesia. Eight 
animals per group were used, if not stated otherwise. Experiments 
were done at the Research Center Borstel under approval of the 
animal ethics committee from the Department of State, Kiel, 
Germany [permit no. V244-7224.121.3 (108-9/14)].
intratracheal il-13 instillation
Mice were anesthetized with isofluorane for 30  s and allowed 
to hang vertically with their mouths open, supported by a taut 
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string placed under their canine teeth. Their tongues were gently 
withdrawn with a blunt forceps to keep them from swallowing. 
Twenty microliters of PBS with or without 5 μg IL-13 (#210-13, 
Peprotech, Hamburg, Germany) was applied onto the base of 
their tongues. When the mice had aspirated the applied solution, 
they were put on their site until they woke up. This intratracheal 
instillation was performed on days 1, 2, and 3. Mice were analyzed 
24 h after the last treatment (permit no. 35-9185.81/G-35/16).
Bronchoalveolar lavage
Lungs were rinsed with 1 ml fresh, ice-cold PBS containing pro-
tease inhibitor (Roche, Basel, Switzerland) via a tracheal canula, 
and obtained cells were counted using a Neubauer chamber. 
Cytospins were prepared for each sample by centrifugation of 
50 μl BAL fluid plus 150 μl of sterile PBS and subsequently stained 
with Diff-Quik (Medion Diagnostics, Duedingen, Switzerland). 
Cells were microscopically differentiated and classified as 
macrophages, neutrophils, eosinophils, or lymphocytes, using 
standard morphologic criteria (42).
cytokine and ige Measurement
Levels of IL 4, IL-5, and IL-13 in serum were measured using 
an enhanced sensitivity cytometric bead array (CBA, Flex Set 
Kits; BD Biosciences, Franklin Lakes, NJ, USA), according to 
the manufacturer’s guidelines. IgE in serum was measured by 
ELISA. Briefly, 96-well high-binding ELISA plates (Greiner, 
Sigma-Aldrich, Deisenhofen, Germany) were coated with 
monoclonal anti-IgE antibodies (clone R35-72, BD Biosciences, 
Heidelberg, Germany) overnight. Serum samples were diluted 
in 1% (w/v) BSA in PBS/0.05% (v/v) Tween 20 and incubated 
overnight at 4°C. Afterward, plates were incubated with anti-
IgE conjugated with HRP (clone 23G3, Southern Biotech, 
Birmingham, AL, USA) for 3  h at room temperature. For the 
colorimetric detection, TMB (Sigma) was used as a substrate. 
Absorbance was measured at 450 nm in ELISA reader (Infinite 
M200, Tecan) and IgE concentrations calculated according to 
standard curve.
Primary Murine Tracheal epithelial 
cell culture
The procedure used for isolation of murine tracheal epithelial 
cells was adapted from Davidson et  al. (43). In brief, mice 
were killed by CO2 inhalation. Tracheas were removed, cut 
lengthways, washed in PBS, and transferred to collection media 
[1:1 mixture of DMEM and Ham’s F12 with 1% (v/v) penicillin–
streptomycin]. Tracheas were then incubated at 4°C overnight 
in dissociation media [44 mM NaHCO3, 54 mM KCL, 110 mM 
NaCl, 0.9  mM NaH2PO4, 0.25  μM FeN3O9, 1  μM sodium 
pyruvate, pH 7.5, and supplemented with 1% (v/v)  penicillin–
streptomycin, 0.1 mg/ml DNaseI (#11284932001, Roche, Basel, 
Switzerland), and 1.4  mg/ml PronaseE (#P5147, Sigma, MO, 
USA)]. Enzymatic digestion was stopped by adding 20% FCS to 
the dissociation media. Epithelial cells were dissociated by gentle 
agitation followed by physical removal of the tracheas. Cells 
were then centrifuged at 1000 × g for 10 min at RT. Cell pellets 
were resuspended in culture medium [1:1 mixture of DMEM 
and Ham’s F12 with 1% penicillin-streptomycin, 5% FCS, and 
120 U/l insulin (#12585014, ThermoFisher Scientific, Waltham, 
MA, USA)], and seeded in a 10 cm cell-culture dish for 2 h at 
37°C. The supernatant was carefully taken off and centrifuged 
at 1000 ×  g for 10  min at RT. Cell pellets from two tracheas 
were resuspended in 200 μl culture medium and seeded in the 
inner well of a transwell (#CLS3470-48EA, Corning® Costar®, 
Sigma, MO, USA) coated with human placenta collagen-IV 
(#C7521, Sigma, MO, USA). The outer well contained 600 μl of 
culture medium. After 7 days, medium from the inner well was 
removed and medium from the outer well was replaced with 
Ultroser G medium [1:1 mixture of DMEM and Ham’s F12 with 
1% penicillin-streptomycin, 2% Ultroser G serum (#15950–017, 
Pall Corporation, Dreieich, Germany)]. After 30 days of culture, 
murine trachea epithelial cells were used for experiments. TER 
was measured using the Millicell® electrical resistance system 
(ERS) (Millipore, Darmstadt, Germany).
Preparation of single-cell suspensions
For analysis of lung homogenate by qPCR, lungs were perfused 
through the right ventricle with PBS. Once lungs appeared white, 
they were removed and sectioned. Dissected lung tissue was then 
incubated with Liberase™ (100  μg/ml, #5401119001, Roche, 
Basel, Switzerland) and DNaseI (200  μg/ml, #11284932001, 
Sigma, MO, USA) at 37°C for 1 h. Digested lung tissue was gen-
tly disrupted by passage through a 19-G needle and afterward 
through a 70-μm pore size nylon cell strainer. Red blood cells 
were lysed using Red blood cell lysis buffer (eBioscience, CA, 
USA). CD11c+ or CD4+ T cells were isolated using the positive 
selection CD11c+ beads or the negative selection CD4+ T Cell 
Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), 
respectively. Magnetically labeled cells were isolated via the 
autoMACS Separator (Miltenyi Biotec). For single cell sus-
pension of splenocytes, spleens were dissected and treated as 
described above without enzymatic digestion.
T cell Differentiation
CD4+ T cells were isolated from a single cell suspension as 
described above. 1 ×  105  cells per well were plated in 96-well 
round bottom plate in 100  μl RPMI plus β-mercaptoethanol 
(50  μM) and stimulated with 4  μl anti-CD3 and anti-CD28-
coated beads (#11456D, ThermoFisher Scientific, Waltham, 
MA, USA)  +  20  ng/ml IL-2 (#402-ML-020, R&D Systems, 
Minneapolis, MN, USA), and either RPMI only (T0) or a Th2 
differentiation solution consisting of 100  ng/ml IL-4 (#214-14, 
Peprotech, Hamburg, Germany), 10 μg/ml anti-IFNγ (#517903, 
BioLegend, San Diego, CA, USA), and 10  μg/ml anti-IL-12 
(#505203, BioLegend, San Diego, CA, USA). Afterward, cells were 
incubated for 3 days at 37°C. On day 4, T cells were restimulated 
with a cell stimulation cocktail including PMA and ionomycin 
(#00-4970, eBioscience, CA, USA) for 3 h and RNA was extracted.
nFκB p65 activity assay
NFκB activity was measured in 1 × 106 cells of a lung homogen-
ate by the TransAM™ NFκB p65 protein assay (Active Motif, 
Carlsbad, CA, USA), an ELISA-based method designed to 
specifically detect and quantify NFκB p65 subunit activation. 
As a positive control, Raji nuclear extract was used that was 
FigUre 1 | socs1Δnls is localized in the cytoplasm. (a) NIH3T3 cells 
were transfected with the indicated eGFP-tagged plasmids and visualized by 
confocal microscopy. Nuclei were counterstained with Hoechst, and 
membranes were stained with CellMask™ dye. Scale bar, 5 μm. (B) NIH3T3 
cells were transfected with eGFP-Socs1 and stimulated with IFNγ (50 ng/ml) 
as indicated. A z-stack was recorded and the ratio of the fluorescence in the 
cytoplasm versus the fluorescence in the nucleus was measured using 
ImageJ by setting an ROI around either the cytoplasm or the nucleus (n = 3 
with 20–50 cells each). Scale bar, 75 μm. (c) Western blot analysis of 
tyrosine phosphorylated STAT1. Raw264.7 cells were transfected with eGFP, 
eGFP-Socs1, or eGFP-Socs1ΔNLS and stimulated with IFNγ (50 ng/ml) as 
indicated. Protein extracts were stained for pY-STAT1 (Tyr701), SOCS1, 
STAT1, and β-actin. Quantification using ImageJ is shown in (D) (n = 3, 
mean + SD, two-way ANOVA including Bonferroni post-test).
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provided with the kit. Wild-type oligonucleotides were used as an 
internal specificity control. The assay was performed according 
to the manufacturer’s protocol and analyzed using a microplate 
absorbance reader (Sunrise reader, Tecan, Salzburg, Austria).
histopathological analysis
Organs were fixed via a tracheal canula under constant pressure 
of 20  cm H2O using 4% (w/v) phosphate buffered paraform-
aldehyde overnight. Tissues were embedded in paraffin. For 
analysis of lung inflammation, 2 μm sections were stained with 
periodic acid–Schiff (PAS) or with hematoxylin and eosin (H&E), 
respectively.
statistics
All experiments were repeated three times unless stated otherwise. 
Data are shown as mean + SD. Statistical significance of compari-
son between two groups was determined by two-tailed unpaired 
Student’s t-test (for data sets following Gaussian distribution), 
Wilcoxon matched pairs test (for data sets not following Gaussian 
distribution), or two-way ANOVA including Bonferroni post-test 
(for multiple comparisons). All statistical analyses were done 
using GraphPad Prism (GraphPad 6.05, San Diego, CA, USA) 
software. Differences were considered significant at *p <  0.05, 
**p < 0.01, and ***p < 0.001.
resUlTs
sOcs1Δnls is localized in the cytoplasm
It has been shown that SOCS1 is able to translocate into the 
cell nucleus due to a functional NLS localized between the 
SH2 domain and the SOCS-box (amino acid 159–173) (33, 34). 
Confirming these results with murine SOCS1 constructs, 
NIH3T3 cells transiently transfected with murine eGFP-Socs1 
showed nuclear localization of the GFP-tagged protein. In 
contrast, eGFP-SOCS1ΔNLS, in which the NLS has been 
replaced by the murine SOCS3 sequence (33), was localized 
more in the cytoplasm (Figure  1A). Cells transfected with 
Socs1wt were also stimulated with IFNγ. Upon stimulation 
enhanced fluorescence in the cytoplasm could be observed, 
suggesting that SOCS1 is partly translocating out of the nucleus 
to inhibit signaling in the cytoplasm (Figure 1B). To verify that 
SOCS1ΔNLS is still functional in the cytoplasm, inhibition of 
IFNγ signaling was analyzed by Western Blotting. Therefore, the 
murine macrophage cell line Raw264.7 was transiently trans-
fected with eGFP, eGFP-Socs1, or eGFP-Socs1ΔNLS. Tyrosine 
phosphorylation of STAT1 was examined upon treatment with 
IFNγ 1–6 h post-transfection (Figures 1C,D). Already 1 h after 
IFNγ treatment, eGFP-Socs1 or eGFP-Socs1ΔNLS transfected 
cells showed lower levels of phosphorylated STAT1 (59 or 
57% as compared to eGFP transfected cells 1  h after IFNγ 
stimulation). Importantly, we could not observe any differences 
in phosphorylated STAT1 levels between eGFP-Socs1 and eGFP-
Socs1ΔNLS-transfected cells. Data suggest that both SOCS1 and 
SOCS1ΔNLS were effectively inhibiting IFNγ-induced STAT1 
tyrosine phosphorylation, which occurs at the level of receptor 
activation.
generation and characterization of Mice 
expressing non-nuclear sOcs1Δnls
To analyze the function of SOCS1 in the cell nucleus in  vivo, 
transgenic mice were established using a BAC containing 
a mutated Socs1 locus with non-nuclear Socs1ΔNLS, eGFP, 
and LuciferaseCBG99, termed MGL (Figure  2A). 2A peptide 
sequences between the protein coding regions result in three 
FigUre 2 | generation of socs1Δnls transgenic mice. (a) Schematic drawing of the bacterial artificial chromosome (BAC) consisting of a mutated Socs1 
locus containing Socs1ΔNLS, eGFP, and LuciferaseCBG99. 2A sequences result in cleavage of the polyprotein. (B) qPCR strategy to specifically detect Socs1 
wildtype (wt) using the primer P1 and P2 in combination with a labeled probe within the NLS, Socs1ΔNLS using the reverse primer P3 in the NLS or total Socs1 
using the primer P1 and P2. BMMs of Socs1+/+MGLtg mice of three different founders were stimulated with IFNγ (50 ng/ml) for 24 h and analyzed for (c) mRNA 
expression of Socs1 wt and Socs1ΔNLS, (D) luciferase activity, and (e) the percentage of GFP positive cells (n = 4–5, mean + SD, two-way ANOVA including 
Bonferroni post-test). (F) CD11c+ cells were isolated from lung homogenate and stimulated with CpG (1 μM), LPS (100 ng/ml), and pI:C (10 μg/ml) for 24 h. 
IL-12p40 protein levels were measured by ELISA (n = 3–5, mean + SD, two-way ANOVA including Bonferroni post-test).
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separate proteins. Thereby, 21 amino acids remain at the 
C-terminus of SOCS1ΔNLS. The combined expression of 
GFP and luciferase together with SOCS1 allows using these 
mice as reporter mice as well. Quantitative real-time PCR was 
established to confirm mRNA expression of Socs1ΔNLS in bone 
marrow-derived macrophages (BMMs) from BAC transgenic 
mice (Figure  2B). To exclude founder-specific effects due to 
different integration sites of the BAC, stable expression and 
regulation of the mutated Socs1 locus was examined in different 
founders. Therefore, offsprings of the founders #53, #45, and 
#29 were analyzed with respect to the expression of Socs1 and 
Socs1ΔNLS in BMMs upon stimulation with IFNγ for 24 h using 
the qPCR strategy as described in Figure 2B. After stimulation 
with IFNγ, mRNA expression of both Socs1 and Socs1ΔNLS were 
induced to a similar amount in all three founders (Figure 2C). 
We observed no differences in expression levels of Socs1wt and 
Socs1ΔNLS. Due to reporter functions of the mutated Socs1 
locus, luciferase assay was performed in BMMs after stimulation 
with IFNγ, showing similar luciferase activity in BMMs for the 
three founders (Figure 2D). In addition, GFP positive BMMs 
were analyzed by flow cytometry (Figure  2E). There was an 
increase in the percentage of GFP-positive cells after stimulation 
with IFNγ, and this was similar for founders #53 (26% ± 9.6), 
#45 (25% ± 8.7), and #29 (21% ± 9.2). Taken together, all three 
founders showed similar expression levels of the mutated Socs1 
locus. Mutant Socs1 expression was also in the same range as 
FigUre 3 | Socs1−/−MGLtg mice survive the early lethal phenotype of 
Socs1−/− mice, but show a reduced body weight. (a) After mating 
Socs1+/− to Socs1+/−MGLtg mice, survival of offsprings was recorded to the 
age of 60 days (n = 28–92 mice per genotype). (B) Mouse body weight 
analysis (n = 10–15 8-week-old mice per gender and genotype, mean + SD, 
Wilcoxon matched pairs test).
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Socs1 wild-type (wt) mRNA, suggesting that different integra-
tion sites did not influence expression of the BAC. Thus, we 
had no indication for a founder specific effect and, therefore, 
further experiments were performed using founder #53 if not 
stated otherwise.
Functional impairment of nFκB inhibition 
in Socs1−/−MGLtg Mice
To analyze the function of SOCS1 in the cell nucleus, Socs1MGLtg 
mice were mated with Socs1+/− mice to generate Socs1−/−MGLtg 
mice, expressing Socs1ΔNLS in an otherwise Socs1-deficient 
background. In order to show that Socs1−/−MGLtg mice indeed 
lack SOCS1 in the cell nucleus, we tried staining of endogenous 
SOCS1 by immunohistochemistry. However, we could not find a 
sufficiently specific antibody that was not staining sections from 
Socs1−/− mice (including newly generated antibodies). Therefore, 
we decided to do a functional approach to verify non-nuclear 
expression of Socs1MGL. It has been reported that nuclear 
SOCS1 limits NFκB signaling by degradation of the NFκB subu-
nit p65 (38). To examine whether NFκB signaling is altered in 
Socs1−/−MGLtg mice, CD11c+ cells were isolated from lungs and 
stimulated ex vivo with TLR agonists. Stimulation of CD11c+ cells 
from Socs1−/−MGLtg mice with CpG-DNA, LPS, and pI:C for 24 h 
led to an increased protein expression of IL-12p40 as compared 
to CD11c+ cells from Socs1+/−MGLtg mice (Figure 2F). The same 
could be shown in CD11c+ cells isolated from spleens (Figure S1 
in Supplementary Material). Data suggest sustained NFκB acti-
vation in Socs1−/−MGLtg mice that was confirmed by transcrip-
tion factor binding assay for p65 (Figure S1 in Supplementary 
Material). We did not detect differences regarding TNFα protein 
levels (Figure S1 in Supplementary Material), which is in full 
accordance with previous findings (38) showing that only a subset 
of NFκB dependent genes is altered in Socs1−/−MGLtg mice. In 
contrast, IL-12p40 induction that needs prolonged binding of 
NFκB to its promoter (44) was sensitive to SOCS1-induced NFκB 
inhibition. The results entirely phenocopy in  vitro data using 
non-nuclear SOCS1ΔNLS, suggesting that Socs1−/−MGLtg mice 
functionally lack SOCS1 in the cell nucleus.
Socs1−/−MGLtg Mice survive the early 
lethal Phenotype as compared to Socs1−/− 
Mice
Socs1−/− mice die within 2–3 weeks due to multiorgan inflam-
mation (24–26). In contrast, Socs1−/−MGLtg mice survived and 
showed no early lethality up to 60 days (Figure 3A), suggesting 
that lack of Socs1wt is rescued by Socs1ΔNLS. Socs1+/− mice 
also showed normal survival indicating that one allele of Socs1 
is sufficient for rescue of the severe knockout phenotype. In 
a small cohort (n  =  4), survival of Socs1−/−MGLtg mice was 
recorded for an extended period (Figure S2A in Supplementary 
Material). Up to 38 weeks, Socs1−/−MGLtg mice appeared healthy 
without overt abnormalities. Although lethality was rescued 
in Socs1−/−MGLtg mice, the mice showed reduced body weight 
both for female and male 8-week-old mice (Figure  3B) sug-
gesting that lack of nuclear SOCS1 results in partial functional 
impairment. In the long-term survival cohort, Socs1−/−MGLtg 
mice showed slightly reduced body weight as well (Figure S2 
in Supplementary Material).
similar mrna expression levels, Protein 
levels, and Protein half-life of sOcs1 
and sOcs1Δnls
To verify that BMMs of Socs1−/−MGLtg mice have similar expres-
sion levels of total Socs1 (both Socs1 and Socs1ΔNLS) as com-
pared to BMMs of Socs1+/− and Socs1+/−MGLtg mice, cells were 
stimulated with IFNγ for 24 h and qPCR was performed to detect 
mRNA of total Socs1 using the qPCR strategy as described in 
Figure 2B. Similar expression of total Socs1 mRNA could be veri-
fied in BMMs of Socs1−/−MGLtg, Socs1+/−, and Socs1+/−MGLtg mice 
(Figure  4A). For further analysis, we generated a new SOCS1 
antibody. This antibody did not detect a band with the expected 
molecular weight for SOCS1 in lysates of BMMs of Socs1−/− mice 
(Figure  4B), thus proving specificity in Western Blot analysis. 
We confirmed expression of SOCS1 and SOCS1ΔNLS protein in 
lysates of BMMs of Socs1+/− and Socs1−/−MGLtg mice stimulated 
with IFNγ for 6 h. The higher molecular weight of SOCS1ΔNLS 
likely resulted from the additional 21 amino acids after cleav-
age of the 2A sequence. In Figure 4C, quantification was done 
normalized to β-actin expression. Comparable protein levels for 
SOCS1 and SOCS1ΔNLS were detected (Figure 4B). The NLS 
of SOCS1 (RRMLGAPLRQRRVR) resembles a bipartite NLS 
composed of two basic stretches. Since the basic amino acid lysine 
is important for marking proteins for the ubiquitin proteasome 
pathway (45, 46), we addressed the question whether exchanging 
the NLS with the SOCS3 counterpart might alter protein half-life. 
We, therefore, performed a cycloheximide (CHX) chase experi-
ment (Figures 4D,E). Six hours post stimulation with IFNγ, CHX 
was added to block nascent protein synthesis. Already after 4 h of 
CHX treatment, there was only 4% of the SOCS1 protein and 12% 
of the SOCS1ΔNLS protein remaining. In summary, we did not 
observe alteration of mRNA expression levels, protein levels, or 
protein half-life upon mutating SOCS1 into SOCS1ΔNLS.
FigUre 4 | similar mrna expression levels, protein levels, and protein half-life of sOcs1 and sOcs1Δnls. (a) Total Socs1 mRNA expression levels in 
BMMs of Socs1+/−, Socs1+/−MGLtg, and Socs1−/−MGLtg mice upon stimulation with IFNγ (50 ng/ml) for 24 h normalized to Actin (ActB) expression (n = 4, 
mean + SD, two-way ANOVA including Bonferroni post-test). (B) Detection of SOCS1 protein in Socs1−/−, Socs1+/−, and Socs1−/−MGLtg mice upon stimulation with 
IFNγ (50 ng/ml) for 6 h using anti-SOCS1 hybridoma cell supernatant. Arrows indicate band for SOCS1 and SOCS1ΔNLS. (c) Quantification of SOCS1 protein for 
Socs1+/− mice and of SOCS1ΔNLS protein for Socs1−/−MGLtg mice compared to β-actin was done using ImageJ (n = 10–13, mean + SD, Student’s t-test).  
(D) Protein stability was assessed performing a cycloheximide (CHX) chase. CHX (100 μg/ml) was added at 6 h poststimulation with IFNγ and BMMs were lysed at 
the indicated timepoints and analyzed for SOCS1 expression by Western Blotting. (e) SOCS1 and SOCS1ΔNLS protein expression was normalized to β-actin in 
order to calculate the percentage of remaining protein relative to its expression prior to the addition of CHX. IkBα was used as a control for effective CHX treatment 
(n = 3–5, mean + SD, two-way ANOVA including Bonferroni post-test).
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Functional regulation of canonical iFnγ 
signaling in Socs1−/−MGLtg Mice
Socs1−/−MGLtg mice survived the early lethal phenotype of 
Socs1−/− mice (Figure  3A). As it is known that Socs1−/− can be 
rescued by the administration of anti-IFNγ antibodies in the 
neonatal period or by using Socs1−/−IFNγ−/− mice (47, 48), we 
hypothesized that canonical IFNγ signaling is not altered in 
Socs1−/−MGLtg mice. To test this hypothesis, tyrosine phospho-
rylation of STAT1 was examined in BMMs upon treatment with 
IFNγ for 1–6  h (Figure  5A). IFNγ signaling was prolonged in 
Socs1−/− mice as shown by the sustained levels of phosphorylated 
STAT1. There was a decline in phosphorylated STAT1 levels for 
both Socs1+/−MGLtg mice (to 20%) and Socs1−/−MGLtg mice (to 
22%) already 4  h after IFNγ stimulation as compared to 58% 
for Socs1−/− mice (Figures  5A,B). No significant differences 
were observed between Socs1+/−MGLtg and Socs1−/−MGLtg mice. 
Analyzing mRNA expression levels of classical IFNγ target genes, 
both iNOS and Irf9 were induced upon stimulation with IFNγ 
to a similar extent in Socs1+/−MGLtg and Socs1−/−MGLtg mice 
(Figure 5C). Of note, the expression levels were also similar to 
Socs1+/− mice, arguing against gene dosage effects. This allows 
interpretation of the data from Socs1−/−MGLtg mice with regards 
to lack of nuclear SOCS1 and not altered concentration of cyto-
plasmic SOCS1. There was a minor, but non-significant, increase 
in the expression level of Icam-1 after 6 h of stimulation in BMMs 
of Socs1−/−MGLtg mice. These findings indicate that SOCS1ΔNLS 
was still able to regulate cytoplasmic signaling pathways and that 
canonical IFNγ signaling was not altered in Socs1−/−MGLtg mice.
Differential expression of a subset of 
non-canonical iFnγ Target genes by 
Socs1−/−MGLtg Mice
To support the hypothesis that canonical IFNγ signaling is not 
altered in Socs1−/−MGLtg mice, whole-genome expression analysis 
was performed. Therefore, BMMs were stimulated with IFNγ for 
24  h and RNA was extracted and subjected to whole-genome 
expression analysis. 1097 genes were differentially regulated 
between untreated and IFNγ stimulated cells, but only 86 genes 
FigUre 5 | canonical iFnγ signaling is not altered in Socs1−/−MGLtg mice. (a) Western blot analysis of tyrosine phosphorylated STAT1 (Tyr701). STAT1 and 
β-actin were used as loading controls. Protein extracts were prepared from BMMs of Socs1−/−, Socs1+/−MGLtg, and Socs1−/−MGLtg mice that were treated with IFNγ 
(50 ng/ml) as indicated. Quantification using ImageJ is shown in (B) (n = 4). (c) mRNA expression of interferon target genes iNOS, Irf9, and Icam-1 are shown 
normalized to Actin (ActB) expression in BMMs of Socs+/−, Socs1+/−MGLtg, and Socs1−/−MGLtg mice treated with IFNγ (50 ng/ml) for 1–6 h (n = 4). Mean + SD is 
presented for each group and significance was assessed using two-way ANOVA including Bonferroni post-test.
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were differentially regulated between BMMs of Socs1−/−MGLtg mice 
and Socs1+/−MGLtg mice. To analyze combinatorial patterns in an 
unbiased fashion, principal component analysis (PCA) was per-
formed. Analysis of untreated BMMs of both genotypes revealed 
close correlation, whereas IFNγ treated BMMs of Socs1−/−MGLtg 
mice and Socs1+/−MGLtg mice were found to be more separated 
(Figure  6A). Most differentially regulated genes were induced 
rather than repressed in Socs1−/−MGLtg mice (Figures 6B,C). The 
top 10 differentially regulated genes (Figure 6D) included signifi-
cantly higher expressed genes in BMMs of Socs1−/−MGLtg mice 
such as Indoleamine 2,3-Dioxygenase 1 (Indo, 11.47-fold) and 
SelectinL (Sell, 6.69-fold) as well as significantly lower expressed 
genes in BMMs of Socs1−/−MGLtg mice such as Src-Like-Adaptor 
(Sla, 0.29-fold) and Growth Differentiation Factor 3 (Gdf3, 0.26-
fold). Those genes were confirmed by qPCR to be differentially 
regulated in Socs1−/−MGLtg mice (Figure  6E). Importantly, no 
canonical IFNγ target genes were differentially regulated in 
Socs1−/−MGLtg mice. Of note, we found 38 genes involved in 
NFκB signaling to be upregulated in BMMs of Socs1−/−MGLtg 
mice and 16 downregulated ones. Pathway annotation was 
performed using the PANTHER classification system among the 
86 genes differentially regulated between IFNγ treated BMMs of 
Socs1+/−MGLtg and Socs1−/−MGLtg mice (Table 1). Instead of IFNγ 
signaling pathway, we found TLR and TNF signaling pathways to 
be dysregulated. For TLR signaling pathway, three genes assigned 
to the signaling pathway were significantly higher expressed and 
five were significantly lower expressed in BMMs of Socs1−/−MGLtg 
mice. For TNF signaling pathway, five genes assigned to the sign-
aling pathway were significantly higher expressed, whereas only 
one was significantly lower expressed in BMMs of Socs1−/−MGLtg 
mice, arguing for a general induction of the pathway. Moreover, 
TFBS among the differentially regulated genes were analyzed 
using the overrepresentation analysis tool oPOSSUM (Table 2). 
TFBS for CTCF, IRF2, and NFκB were overrepresented among 
the differentially regulated genes in Socs1−/−MGLtg mice with 21, 
8, and 56 genes, respectively. STAT1 as classical transcription 
factor for IFNγ signaling was not overrepresented among the 
differentially regulated genes, strengthening the hypothesis of 
functional regulation of canonical IFNγ signaling by Socs1ΔNLS 
in Socs1−/−MGLtg mice. In summary, whole genome expression 
analysis revealed a small subset of non-canonical IFNγ-regulated 
genes that were differentially regulated in Socs1−/−MGLtg mice 
with an overrepresentation of TFBS for NFκB.
Socs1−/−MGLtg Mice spontaneously Develop 
low-grade inflammation in the lung
Although inhibition of IFNγ signaling by SOCS1ΔNLS was 
still functional in Socs1−/−MGLtg mice, gene expression analysis 
indicated that differences due to lack of SOCS1 in the cell nucleus 
were present. We closely analyzed Socs1−/−MGLtg mice for disease 
symptoms. Histopathological analysis revealed low-grade inflam-
mation in lung and liver in a significant number of Socs1−/−MGLtg 
mice (Table S2 in Supplementary Material). However, no dif-
ferences were observed in serum AST and ALT levels (Figure 
S3 in Supplementary Material). We, therefore, focused on lung 
histopathology. Infiltrates in lung tissue were observed in 45% 
of the lung sections of Socs1−/−MGLtg mice (Figure 7A) in three 
different founders. PAS staining was performed to identify mucus 
producing cells, revealing a higher number of PAS positive cells 
in the lungs of Socs1−/−MGLtg mice (Figure  7B). In addition, 
TaBle 1 | Pathway annotation [protein analysis through evolutionary relationships (PanTher) classification system].
Pathway iD input/background induced genes repressed genes p-Value
TLR signaling pathway 8/101 CD40, Cxcl10, Jun Ccl3, Ccl4, Ccl5, Tlr7, Tlr8 0.00129
TNF signaling pathway 6/109 Socs3, Fas, Tnfaip3, Cxcl10, Jun Ccl5 0.056
Differentially expressed genes in Socs1−/−MGLtg mice upon IFNγ stimulation showing a log2-fold change (≤−1 or ≥1) and p ≤ 0.05 were analyzed to classify and identify gene 
functions.
FigUre 6 | subset of non-classical iFnγ target genes is differentially regulated in Socs1−/−MGLtg mice. BMMs were stimulated with IFNγ for 24 h, RNA 
was extracted and subjected to whole-genome expression analysis (a) principal component analysis (PCA). The two principal components and their fraction of the 
overall variability of the data (%) are shown on the x-axis and the y-axis. Clusters of experiments are circled (95% confidence interval ellipse) and annotated as 
Socs1+/−MGLtg ctrl and Socs1−/−MGLtg ctrl for untreated samples and Socs1+/−MGLtg + IFNγ and Socs1−/−MGLtg + IFNγ for IFNγ-stimulated samples. (B) Volcano 
plot showing the genes that were differentially expressed between BMMs of Socs1+/−MGLtg and Socs1−/−MGLtg mice. Only significant values (p ≤ 0.05) were 
considered showing a log2-fold change ≤−1 (red points) or ≥1 (blue points). (c) Heat map visualizing hierarchical clustering analysis based on the expression levels 
of genes that are differentially expressed between BMMs of Socs1+/−MGLtg and Socs1−/−MGLtg mice. Red indicates higher expression and blue indicates lower 
expression of the corresponding gene in Socs1−/−MGLtg mice, respectively (n = 4). (D) 10 most prominently up- and downregulated genes according to their fold 
change. (e) Quantitative RT-PCR was performed using RNA from BMMs stimulated with IFNγ for 24 h (n = 3, mean + SD, Student’s t-test).
TaBle 2 | oPOssUM analysis of overrepresented transcription factor binding sites.
TFBs input/background class Family z-score Fischer score
CTCF 21/86 Zinc coordinating ββα zinc finger 14.88 5.01
IRF2 8/86 Winged helix-turn-helix IRF 14.343 4.42
NFκB 56/86 Ig fold Rel 12.24 2.28
Differentially expressed genes in Socs1−/−MGLtg mice upon IFNγ stimulation showing a log2-fold change (≤−1 or ≥1) and p ≤ 0.05 were uploaded to identify overrepresented 
transcription factor binding sites among those genes. Transcription factors enriched in the corresponding gene set were CTCF, IRF2, and NFkB.
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FigUre 8 | enhanced airway eosinophilia in Socs1−/−MGLtg mice upon 
OVa sensitization and challenge. Mice were sensitized with OVA/Alum or 
PBS i.p. on days 1, 14, and 21, followed by a challenge with 1% OVA aerosol 
or PBS on days 26, 27, and 28. (a) Total numbers of leukocyte 
subpopulations in BAL fluids are represented. (B) Levels of IL-4, IL-5, and 
IL-13 in serum were measured by ELISA (n = 6–8, mean + SEM, two-way 
ANOVA including Bonferroni post-test).
FigUre 7 | Socs1−/−MGLtg mice show low-grade inflammation in the 
lung. (a) H&E-stained airway cross sections. Arrow highlighting infiltrating 
cells. Scale bar, 100 μm. One lung section per mouse was analyzed. (B) 
Periodic acid–Schiff (PAS) stained airway cross sections. Arrow highlighting 
PAS positive cells. Scale bar, 200 μm. (c) IgE concentration in serum 
(n = 9, mean + SD, Wilcoxon matched pairs test). (D) Expression levels of 
Foxp3, Gata3, Tbet, and Rorc in sorted CD4+ T cells in the lung of both 
founder #53 and #29 (n = 7–11, mean + SD, two-way ANOVA including 
Bonferroni post-test). (e) Naive CD4+ T cells were differentiated under T0 
conditions (RPMI only) or under Th2 conditions (100 ng/ml IL-4, 10 μg/ml 
anti-IFNγ, and 10 μg/ml anti-IL-12p40) for 3 days and restimulated using 
PMA and ionomycin. Expression of Gata3 was examined by qPCR (n = 3, 
mean + SD, two-way ANOVA including Bonferroni post-test). (F) 
Expression levels of IL-4, IL-5, and IL-13 in total lung homogenates of both 
founder #53 and #29 (n = 7–11, mean + SD, one-way ANOVA including 
Bonferroni post-test).
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Socs1−/−MGLtg mice showed 19.4-fold increased serum IgE levels 
(Figure 7C). Since SOCS1 has been shown to be important for 
T helper cell differentiation (31, 49, 50), we analyzed whether 
Socs1−/−MGLtg mice have a T helper cell bias. Therefore, CD4+ 
T cells were isolated from lung homogenates and expression 
of transcription factors for T helper cell subsets was examined 
by qPCR (Figure  7D). Socs1−/−MGLtg mice showed a 4.2-fold 
increase of Gata3+ cells, suggesting a higher number of Th2 cells. 
Using an in vitro differentiation assay, naive CD4+ T cells from 
Socs1−/−MGLtg mice tend to express more Gata3 as compared 
to CD4+ T cells from Socs1+/−MGLtg mice, even under neutral 
conditions (T0, RPMI only) (Figure  7E). Increased mRNA 
expression of IL-4, IL-5, and IL-13 in complete lung homogenates 
of Socs1−/−MGLtg mice compared to both Socs+/−MGLtg and Socs+/− 
mice confirmed this Th2 bias (Figure  7F). Notably, we found 
one population of Socs1−/−MGLtg mice with a strong expression 
of Gata3 and Th2 type cytokines in lung homogenates, and the 
second population showing a weaker Th2 bias, consistent with 
the fact that we could observe infiltrates in the lung only in 45% 
of the mice.
increased airway eosinophilia in 
Socs1−/−MGLtg Mice in an OVa 
experimental asthma Model
To analyze if this Th2 bias is of physiological relevance, mice 
were challenged by inhaled antigen. Socs1−/−MGLtg mice were 
subjected to a well-established protocol for the induction of 
experimental asthma (41, 51). Upon OVA sensitization and 
OVA aerosol challenge, Socs1−/−MGLtg mice showed increased 
airway eosinophilia (21.5 × 104 cells/ml in BALF) as compared 
to Socs1+/−MGLtg control mice (7.3  ×  104  cells/ml in BALF) 
(Figure  8A). In addition, IL-4 and IL-13 levels were higher in 
BAL fluid of Socs1−/−MGLtg mice upon OVA sensitization and 
challenge as compared to Socs1+/−MGLtg mice (Figure 8B). IL-5 
FigUre 9 | Trachea epithelial cells from Socs1−/−MGLtg mice show 
alterations. (a) Enhanced expression levels of IL-25, IL-33, and Tslp in total 
lung homogenates of both founder #53 and #29 (n = 7–11, mean + SD, one-
way ANOVA including Bonferroni post-test). (B) Enhanced expression levels 
of IL-33 and Ccl26 in primary murine trachea epithelial cells (n = 5, 
mean + SD, one-way ANOVA including Bonferroni post-test). (c) Decreased 
transepithelial electrical resistance in trachea epithelial cells from 
Socs1−/−MGLtg mice as measured with the Millicell® electrical resistance 
system (ERS) (n = 5, mean + SD, one-way ANOVA including Bonferroni post-
test).
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levels upon challenge were induced, yet, showed no difference 
with respect to expression of the non-nuclear SOCS1. Similar 
effects were observed in Socs1−/−MGLtg mice upon intratracheal 
IL-13 instillation. IL-13-treated mice of all genotypes developed 
neutrophilia in the lung. Socs1−/−MGLtg mice additionally showed 
enhanced influx of eosinophils (however non-significant) and 
lymphocytes (Figure S4A in Supplementary Material). In addi-
tion, Socs1−/−MGLtg mice showed increased mRNA expression 
of IL-4, IL-5, and IL-13, which was even more pronounced 
upon IL-13 treatment. Socs1 induction in all three genotypes 
upon IL-13 instillation was equal (Figure S4B in Supplementary 
Material).
Disrupted epithelial integrity in 
Socs1−/−MGLtg Mice
Since Socs1−/−MGLtg mice showed enhanced expression of IL-25, 
IL-33, and Tslp in lung homogenates (Figure  9A), we closer 
analyzed the airway epithelium. Therefore, tracheas were isolated 
and trachea epithelial cells were differentiated in an air–liquid 
interface (ALI) using transwells. Increased IL-33 expression could 
be verified in isolated trachea epithelial cells from Socs1−/−MGLtg 
mice. In addition, Ccl26 expression was examined since it is 
known for the recruitment of eosinophils (52). Indeed, trachea 
epithelial cells from Socs1−/−MGLtg mice expressed significantly 
more Ccl26 as compared to cells from Socs1+/−MGLtg mice. 
Interestingly, we found decreased TER in trachea epithelial cells 
from Socs1−/−MGLtg mice as compared to cells from Socs1+/− and 
Socs1+/−MGLtg mice. This suggests disrupted epithelial integrity 
and might explain low-grade inflammation observed in the lungs 
of Socs1−/−MGLtg mice.
DiscUssiOn
Suppressor of cytokine signaling 1 is a classical negative feedback 
regulator of cytoplasmic JAK/STAT signaling (4–6). However, 
it has been described that SOCS1 is also localized in the cell 
nucleus (33, 34), yet, the function of SOCS1 in the cell nucleus 
in vivo remains elusive. To study the role of nuclear SOCS1, we 
generated transgenic mice using a BAC containing a mutated 
Socs1 (Socs1ΔNLS) that fails to translocate in the cell nucleus, 
which is expressed together with eGFP and LuciferaseCBG99 
(MGL). Using BACs to create transgenic mice is a commonly 
used approach (53–56), which allows manipulating genes 
embedded within their genetic regulatory environment. We 
aimed for similar gene regulation of Socs1wt and Socs1ΔNLS 
and therefore carefully controlled that the locus of BAC-vector 
integration produced similar transcript amounts of Socs1wt and 
Socs1ΔNLS (Figure  4). There were no detectable differences 
regarding expression and regulation of Socs1wt or Socs1ΔNLS 
mRNA between three different founders (Figure  2). Next, we 
investigated whether there is a gene dosage effect. We cannot 
fully exclude that increased localization of SOCS1ΔNLS to the 
cytoplasm contributes to the observed effects although we did 
not find any indication that this construct is more effective in 
inhibiting JAK/STAT signaling. In fact, data from Socs1+/− and 
Socs1+/−MGLtg mice were very similar, thus arguing against 
any side effect due to increased cytoplasmic localization of 
SOCS1ΔNLS. In contrast to Socs1−/− mice, Socs1+/− mice lacked 
pathological levels of IFNγ (24) and were found to be pheno-
typically normal (26). We confirm these data by showing that 
Socs1+/− mice had normal survival (Figure  3) indicating that 
one allele of Socs1 is sufficient for rescue of the severe knockout 
phenotype. Analyzing expression of IFNγ-dependent genes 
(Figure 5) and the lung phenotype (Figures 7 and 9), we found 
no difference between Socs1+/− and Socs1+/−MGLtg mice, arguing 
against a gene dosage effect and for a localization-specific effect 
resulting in eosinophilic lung inflammation in Socs1−/−MGLtg 
mice. As reported previously, we found that SOCS1 is expressed 
at low levels and is relatively short-lived (57), but can be induced 
by IFNγ (49). The NLS of SOCS1 (RRMLGAPLRQRRVR, 
amino acid 159–173) resembles a bipartite NLS composed of 
two basic stretches. Lysine as a basic amino acid is important 
for the ubiquitin proteasome pathway, linking ubiquitin chains 
onto proteins to mark them for degradation via the proteasome 
(45, 46). Therefore, we addressed the question whether exchang-
ing the NLS with the SOCS3 counterpart might alter protein 
half-life (Figures  4D,E). However, protein half-life was not 
altered upon exchanging the NLS corresponding part of SOCS1 
with SOCS3 (SOCS1ΔNLS). In general, the results confirm 
previously described expression patterns of SOCS1, indicat-
ing that the transgene has integrated in a region accessible for 
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transcriptional regulation and that using BAC transgenic mice 
is a valid approach to study the function of SOCS1 in the cell 
nucleus.
In order to show that Socs1−/−MGLtg mice indeed lack SOCS1 
in the cell nucleus, we tried staining of SOCS1 on lung sections 
by immunohistochemistry. However, we could not find a spe-
cific antibody that was not staining sections from Socs1−/− mice. 
Therefore, we decided to apply a functional approach to verify 
non-nuclear expression of Socs1MGL. SOCS1 has been shown 
to induce proteasomal degradation of NFκB (36, 37) by interac-
tion with p65 in the cell nucleus, thereby limiting induction of 
a subset of NFκB-dependent genes (38). Lack of nuclear SOCS1 
leads to sustained activation of NFκB that could be confirmed 
using a transcription factor assay specifically for p65 (Figure 
S1 in Supplementary Material). Socs1−/−MGLtg mice indeed 
showed sustained IL-12p40 protein levels in CD11c+ cells of 
the lung and spleen (Figure 2F). We did not detect differences 
regarding TNFα protein levels (Figure S1 in Supplementary 
Material). Unlike TNFα that shows fast NFκB recruitment to a 
constitutively and immediately accessible promoter, IL-12p40 
is a gene that needs prolonged binding of NFκB to its promoter 
(44). Only a small subset of NFκB-dependent genes that is 
dependent on prolonged transcriptional activation is affected 
by sustained activation of p65 such as IL-12p40. Taken together, 
findings in Socs1−/−MGLtg mice are fully consistent with previ-
ously described in vitro data using non-nuclear SOCS1ΔNLS 
(38), suggesting that Socs1−/−MGLtg mice lack SOCS1 in the cell 
nucleus. In addition, we found a substantial number of differ-
entially expressed genes annotated to TLR and TNF signaling, 
and NFκB-binding sites were overrepresented among those 
genes (Tables 1 and 2).
Socs1−/−MGLtg mice, expressing only non-nuclear mutant 
Socs1 (Socs1ΔNLS), survive the early lethal phenotype of 
Socs1−/− mice (Figure 3; Figure S2 in Supplementary Material) 
that otherwise die within 3  weeks due to excessive immune 
signaling and multiorgan inflammation (24–26). The data show 
that SOCS1ΔNLS was sufficient to rescue lack of wild-type 
SOCS1. The disease in Socs1 knockout mice mainly depends 
on hyperresponsiveness to IFNγ as it can be prevented in the 
neonatal period by the administration of anti-IFNγ antibodies 
or by using Socs1−/−IFNγ−/− mice (47, 48). Therefore, we hypoth-
esized that canonical IFNγ signaling might still be efficiently 
regulated by Socs1ΔNLS. IFNγ binds to the IFNγ receptor 
complex, activates JAK1/2, and subsequently leads to tyrosine 
phosphorylation of STAT1 (pY-STAT1). pY-STAT1 dimers in 
turn translocate into the nucleus and activate transcription of 
“canonical” IFNγ-responsive genes (15, 16, 58). Socs1−/−MGLtg 
mice showed functional regulation of canonical IFNγ signaling, 
as shown by unaltered pY-STAT1 levels and whole-genome 
expression analysis in BMMs (Figures 5 and 6). In addition to 
canonical signaling, a number of studies have shown that pY-
STAT1-independent pathways also exist (17–19). Besides their 
localization on the plasmamembrane, IFNAR1 and TYK2 have 
been shown to occur in the nucleus as well (21, 22). In addition, 
it has been shown that STATs translocate into the nucleus in a 
pY-independent manner, where they activate expression of only 
a subset of “non-canonical” IFNγ-induced genes (23). Indeed, 
a subset of non-canonical IFNγ target genes were differentially 
regulated comparing BMMs of Socs1−/−MGLtg and Socs1+/−MGLtg 
mice. Pathway annotation did not reveal IFNγ signaling to 
be differentially regulated, confirming that Socs1ΔNLS was 
still able to regulate cytoplasmic signaling pathways and that 
canonical IFNγ signaling was not altered in Socs1−/−MGLtg mice. 
We observed minor, but non-significant differences in Icam-1 
expression upon stimulation with IFNγ comparing BMMs of 
Socs1+/−MGLtg and Socs1−/−MGLtg mice (Figure 5). This is in line 
with literature showing that upregulation of ICAM-1 by IFNγ is 
inhibited by SOCS1 (59) with its inhibitory capacity depending 
on the functional NLS of SOCS1 (34).
We closely analyzed Socs1−/−MGLtg mice for disease symptoms 
and found reduced body weight and spontaneous development 
of low-grade inflammation in the lung (Figure 7). Expression of 
SOCS1 in the lung has been reported for alveolar macrophages 
(60), bronchial epithelial cells (61), and eosinophils (62). 
Mice fully deficient for SOCS1 show extensive hematopoietic 
infiltration in the lung (26), arguing that SOCS1 is involved in 
immune regulation in the lung. Increased serum IgE levels in 
Socs1−/−MGLtg mice suggest an allergic airway disease. To ana-
lyze whether the Th2 bias observed in Socs1−/−MGLtg mice is of 
physiological relevance, mice were challenged by either inhaled 
OVA or IL-13. Both, upon OVA sensitization and challenge as 
well as IL-13 instillation, Socs1−/−MGLtg mice showed increased 
airway eosinophilia (Figure  8; Figure S4 in Supplementary 
Material). This is in line with previous data showing that 
serum IgE levels and infiltrating eosinophils were considerably 
increased in the lungs of OVA-treated Socs1−/−IFNγ−/− mice (63). 
So far, it is unclear how the lack of nuclear SOCS1 leads to airway 
eosinophilia. One hypothesis is that SOCS1 is crucial to main-
tain epithelial cell barrier function (Figure S5 in Supplementary 
Material). Sustained NFκB signaling might lead to an activation 
of the epithelium. We observed increased expression of the 
epithelial cell-derived cytokine IL-33 in primary murine trachea 
epithelial cells of Socs1−/−MGLtg mice (Figure  9). Since it has 
been shown previously (64) that IL-33 has an impact on epithe-
lial integrity, higher IL-33 levels in Socs1−/−MGLtg mice might 
result in epithelial barrier disruption. Enhanced barrier perme-
ability in turn might facilitate other immune cells such as DCs 
in initiate host defense mechanisms resulting in inflammation 
(65). Triggering of pattern recognition receptors on epithelial 
cells has been reported to release of IL-33 leading to an activa-
tion of DCs (66–68). Recently, it has been shown that IL-33 is 
constitutively expressed in the cell nucleus in epithelial cells (69) 
where direct interaction between SOCS1 and IL-33 might be 
possible. Furthermore, IL-13 has been shown to downregulate 
junctional components including E-cadherin in bronchiolar 
epithelial cells leading to disruptive effects on airway epithelial 
barrier function (70) and explaining why we see stronger eosino-
philia upon IL-13 treatment. Indeed, higher SOCS1 expression 
has been shown to inhibit IL13 induced CCL26 expression in 
epithelial cells in vitro whereas reduced SOCS1 expression was 
correlated with enhanced airway eosinophilia (71). Epithelial 
cells of Socs1−/−MGLtg mice produce more CCL26 which in turn 
attracts eosinophils resulting in airway eosinophilia (Figure S5 
in Supplementary Material).
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The second hypothesis is that hematopoietic cells are 
the key players involved in nuclear SOCS1 induced airway 
eosinophilia. Lee et  al. showed that serum IgE levels and 
infiltrating eosinophils were considerably increased in the 
lungs of OVA-treated Socs1−/−IFNγ−/− mice (63). They suggest 
that regulation of SOCS1 mainly affects hematopoietic cells, 
not epithelial cells. McCormick et  al. showed that reduced 
expression of SOCS1 has been shown to prolong IL-4-
induced IRS-2 tyrosine phosphorylation and enhanced M2 
differentiation (72). IRS-2 also plays a major role in allergic 
lung inflammation and remodeling (73). In addition, SOCS1 
is important in helper T cell differentiation (5, 6, 49): it is 
rapidly induced in response to many cytokines, including IFNγ 
and IL-4 and it is an important negative feedback inhibitor of 
both signaling pathways. When Socs1−/− mice are crossed with 
either an IFNγ−/− or STAT6−/− mice, survival is prolonged (47, 
50), indicating that SOCS1 regulates both IFNγ-driven Th1 
and IL-4-driven Th2 responses. Supporting this finding, CD4+ 
T cells from Socs1−/− mice spontaneously differentiate into Th1 
and Th2 cells, thereby producing IFNγ and IL-4, respectively 
(31, 50). It has previously been shown in vitro that SOCS1 is 
a negative regulator of Th2-dependent pathways, achieved by 
inhibition of pSTAT6 (74). In line with this, Socs1−/−MGLtg 
mice showed enhanced percentage of Gata3+ CD4+ cells and 
increased expression of IL-4, IL-5, and IL-13, suggesting that 
nuclear SOCS1 plays a role in T cell differentiation. Even 
under neutral conditions, CD4+ T cells of Socs1−/−MGLtg mice 
tend to differentiate into Gata3+ cells, arguing for a T cell 
intrinsic effect of nuclear SOCS1. Increased Th2 cytokines in 
Socs1−/−MGLtg mice could in turn act on the epithelial cells. 
Further clarification will require generating bone marrow 
chimeras to differentiate between contributions of nuclear 
SOCS1 in cells sensitive for radiation (hematopoietic cells) 
or radiation-resistant cells (such as epithelial cells).
There have been several publications linking SOCS1 expres-
sion with allergic diseases such as asthma (61, 71, 74, 75). Gielen 
et  al. (61) observed that nuclear SOCS1 suppressed rhinovirus 
induction of interferons, which is discussed to be associated with 
increased susceptibility to virus exacerbation in severe asthma. 
Since induction of interferons occurs via pattern recognition 
receptors that are linked to NFkB signaling, inhibition of NFkB 
signaling by nuclear SOCS1 might be a possible mechanism for 
the control of immunity in the lung. Socs1 gene expression was 
significantly lower expressed in the airways of severe asthmatics 
compared with mild/moderate asthmatics, and was inversely 
associated with airway eosinophilia (71, 74), suggesting that the 
absence of SOCS1 leads to Th2 bias. Using Socs1−/−MGLtg mice, 
we have shown for the first time, that not only the presence of 
SOCS1 but also the localization is crucial for effective regulation 
of Th2 responses. A study assessing functional variants of Socs1 
within a population of adult Japanese asthma patients found a sig-
nificant association between the Socs1 promoter polymorphism 
(−1478CA < del) and adult asthma. It is suggested that promoter 
polymorphism leads to increased SOCS1 and inhibition of inter-
ferons, leading to higher susceptibility to virus-induced asthma 
exacerbations (75). Another study showed that expression of 
nuclear SOCS1 is increased in atopic asthmatic patients (61), 
which was associated with suppression of rhinovirus-induced 
interferons. The findings allow the conclusion that SOCS1 in 
the cell nucleus plays an important role in the regulation of local 
immunity in the lung that needs to be further investigated.
Taken together, Socs1−/−MGLtg mice showed functional regula-
tion of canonical IFNγ signaling, but differential regulation of 
a subset of IFNγ-dependent genes, possibly due to alteration 
in NFκB signaling pathway. Socs1−/−MGLtg mice spontaneously 
developed low-grade airway inflammation and had increased 
serum IgE levels and Th2 cytokines in the lung. Upon OVA sen-
sitization and OVA aerosol challenge as well as IL-13 instillation, 
Socs1−/−MGLtg mice reacted with augmented influx of eosinophils, 
arguing for an immune regulatory function of nuclear SOCS1 in 
the lung. We present a valuable tool to study the nuclear function 
of SOCS1 in vivo that allows investigating local immune regula-
tion in the lung by nuclear SOCS1.
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